Pre-Made Luspatercept Biosimilar, Fusion Protein targeting GDF11 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting BMP-11/BMP11/VHO for drug discovery and mechanism of action (MOA) research

Pre-Made Luspatercept Biosimilar, Fusion Protein targeting GDF11 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting BMP-11/BMP11/VHO is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Luspatercept is a recombinant fusion protein derived from human activin receptor type IIb (ActRIIb) linked to a protein derived from immunoglobulin G. It binds TGF (transforming growth factor beta) superfamily ligands to reduce SMAD signaling. Inhibition of this family results in increased expression of blood cell precursors and improves parameters associated with ineffective production of red blood cells. Luspatercept is used to treat anemia in adults who are receiving blood transfusions to treat thalassemia (an inherited condition that causes a low number of red blood cells). Luspatercept is also used to treat anemia in adults with certain types of myelodysplastic syndrome.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-903-1mg	1mg	3090
GMP-Bios-INN-903-10mg	10mg	Inquiry
GMP-Bios-INN-903-100mg	100mg	Inquiry
GMP-Bios-INN-903-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Luspatercept Biosimilar, Fusion Protein targeting GDF11 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting BMP-11/BMP11/VHO
INN Name	Luspatercept
Target	GDF11
Format	Fusion Protein
Derivation	human
Species Reactivity	human
CH1 Isotype	Fusion - [ACVR2B (activin A receptor type IIB, ActR-IIB, ActRIIB)]2 - IGHG1 Fc (Fragment constant)
VD LC	Fusion - [ACVR2B (activin A receptor type IIB, ActR-IIB, ActRIIB)]2 - IGHG1 Fc (Fragment constant)
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Celgene corporation (Summit USA) / Acceleron Pharma, Inc (Cambridge UK)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0